Chief Strategist, Dhaval Joshi
Competitive Advantage
- Investment strategy, clear asset allocation and proprietary indicators provide clients with key inputs to enhance returns and reduce risk on European investment portfolios.
- Discussion of key investment themes assist clients assess the big picture and underlying forces that drive European economies and markets.
- Actionable and specific investment recommendations for all European asset classes, including sector and country themes, allow clients to capitalize on profit opportunities and avoid risk.
Investment strategy and timing advice for all asset classes in the entire Euro area, U.K., Sweden and Switzerland.
Components
Weekly Reports
The backbone of the service, reports are emailed every Thursday and contain a discussion of the key investment themes, provide clients with portfolio strategy advice and specific investment recommendations along with updates of our proprietary indicators.
Special Reports
Focusing on original investment ideas, special reports drill down into key issues affecting the European investment outlook. Reports include both in-depth and brief pieces on timely opportunities or risks.
Dhaval Joshi, Chief Strategist
Dhaval Joshi joined BCA in February 2011 as Chief Strategist of BCA’s European Investment Strategy service. Previously, he was Chief Strategist at RAB Capital, a U.K. based hedge fund with $1 billion of assets. Prior to that position, Dhaval was the Global Strategist at Societe Generale where he consistently received high rankings in external surveys, including the Extel award for best new pan-European analyst in 2000. From 1993 – 1999 he was an Investment Manager at JP Morgan Fleming, specializing in applied behavioral finance. Dhaval’s commentary and analysis have regularly appeared in leading financial publications such as the Financial Times and The Economist.
He holds a M.A. (Hons) from Cambridge University, England and is an Affiliate of the Institute of Actuaries.
Download a PDF of European Investment Strategy.
Click here for a trial to BCA Research.
